Myelodysplastic syndrome

RETRACTED ARTICLE: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML


Chaperone-mediated autophagy (CMA) is a highly selective form of autophagy. During CMA, the HSC70 chaperone carries target proteins endowed with a KFERQ-like motif to the lysosomal receptor LAMP2A, which then translocate them into lysosomes for degradation. In the present study, we scrutinized the mechanisms underlying the response and resistance to Azacytidine (Aza) in MDS/AML cell lines and bone marrow CD34+ blasts from MDS/AML patients. In engineered Aza-resistant MDS cell lines and some AML cell lines, we identified a profound defect in CMA linked to the absence of LAMP2A. LAMP2 deficiency was responsible for Aza resistance and hypersensitivity to lysosome and autophagy inhibitors. Accordingly, gain of function of LAMP2 in deficient cells or loss of function in LAMP2-expressing cells rendered them sensitive or resistant to Aza, respectively. A strict correlation was observed between the absence of LAMP2, resistance to Aza and sensitivity to lysosome inhibitors. Low levels of LAMP2 expression in CD34+ blasts from MDS/AML patients correlated with lack of sensitivity to Aza and were predictive of poor overall survival. We propose that CD34+/LAMP2Low patients at diagnosis or who become CD34+/LAMP2Low during the course of treatment with Aza might benefit from a lysosome inhibitor already used in the clinic.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Data availability

All results and datas presented in this article are available in main or supplemental figures. Characteristics of patients presented in Fig. 6a are available in Table 1. Patients DATA sets relative to Fig. 6c, Sup. Figure 13C and D are available on the Cbioportal website (TCGA NEJM 2013).


  1. 1.

    Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872–85.

    PubMed  CAS  Google Scholar 

  2. 2.

    Fenaux P. Myelodysplastic syndromes: from pathogenesis and prognosis to treatment. Semin Hematol. 2004;41(2Suppl 4):6–12.

    PubMed  Google Scholar 

  3. 3.

    Mufti G, List AF, Gore SD, Ho AY. Myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2003;1:176–99.

  4. 4.

    Mufti GJ. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004;17:543–57.

    PubMed  Google Scholar 

  5. 5.

    Gardin C, Chaibi P, de Revel T, Rousselot P, Turlure P, Miclea JM, et al. Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Reflexion en Hematologie. Leukemia. 1997;11:16–21.

    PubMed  Google Scholar 

  6. 6.

    Ades L, Santini V. Hypomethylating agents and chemotherapy in MDS. Best Pract Res Clin Haematol. 2013;26:411–9.

    PubMed  Google Scholar 

  7. 7.

    Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670–7.

    PubMed  PubMed Central  Google Scholar 

  8. 8.

    Itzykson R, Fenaux P. Epigenetics of myelodysplastic syndromes. Leukemia. 2014;28:497–506.

    PubMed  Google Scholar 

  9. 9.

    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.

    PubMed  PubMed Central  Google Scholar 

  10. 10.

    Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–40.

    PubMed  Google Scholar 

  11. 11.

    Santini V, Prebet T, Fenaux P, Gattermann N, Nilsson L, Pfeilstocker M, et al. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leuk Res. 2014;38:1381–91.

    PubMed  Google Scholar 

  12. 12.

    Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322–7.

    PubMed  PubMed Central  Google Scholar 

  13. 13.

    Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell. 2013;24:379–93.

    PubMed  Google Scholar 

  14. 14.

    Piao S, Amaravadi RK. Targeting the lysosome in cancer. Ann N Y Acad Sci. 2016;1371:45–54.

    PubMed  Google Scholar 

  15. 15.

    Kallunki T, Olsen OD, Jaattela M. Cancer-associated lysosomal changes: friends or foes? Oncogene. 2013;32:1995–2004.

    PubMed  Google Scholar 

  16. 16.

    Cluzeau T, Robert G, Puissant A, Jean-Michel K, Cassuto JP, Raynaud S, et al. Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy. Cell Cycle. 2011;10:2339–43.

    PubMed  Google Scholar 

  17. 17.

    Cluzeau T, Dubois A, Jacquel A, Luciano F, Renneville A, Preudhomme C, et al. Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. Oncotarget. 2014;5:4384–91.

    PubMed  PubMed Central  Google Scholar 

  18. 18.

    Guo S, Liang Y, Murphy SF, Huang A, Shen H, Kelly DF, et al. A rapid and high content assay that measures cyto-ID-stained autophagic compartments and estimates autophagy flux with potential clinical applications. Autophagy. 2015;11:560–72.

    PubMed  PubMed Central  Google Scholar 

  19. 19.

    Li P, Ji M, Lu F, Zhang J, Li H, Cui T, et al. Degradation of AF1Q by chaperone-mediated autophagy. Exp Cell Res. 2014;327:48–56.

    PubMed  Google Scholar 

  20. 20.

    Massey A, Kiffin R, Cuervo AM. Pathophysiology of chaperone-mediated autophagy. Int J Biochem Cell Biol. 2004;36:2420–34.

    PubMed  Google Scholar 

  21. 21.

    Kaushik S, Massey AC, Mizushima N, Cuervo AM. Constitutive activation of chaperone-mediated autophagy in cells with impaired macroautophagy. Mol Biol Cell. 2008;19:2179–92.

    PubMed  PubMed Central  Google Scholar 

  22. 22.

    Kaushik S, Cuervo AM. Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol. 2012;22:407–17.

    PubMed  PubMed Central  Google Scholar 

  23. 23.

    Orenstein SJ, Cuervo AM. Chaperone-mediated autophagy: molecular mechanisms and physiological relevance. Semin Cell Dev Biol. 2010;21:719–26.

    PubMed  PubMed Central  Google Scholar 

  24. 24.

    Dice JF. Chaperone-mediated autophagy. Autophagy. 2007;3:295–9.

    PubMed  CAS  Google Scholar 

  25. 25.

    Massey AC, Kaushik S, Sovak G, Kiffin R, Cuervo AM. Consequences of the selective blockage of chaperone-mediated autophagy. Proc Natl Acad Sci USA. 2006;103:5805–10.

    PubMed  Google Scholar 

  26. 26.

    Koga H, Martinez-Vicente M, Arias E, Kaushik S, Sulzer D, Cuervo AM. Constitutive upregulation of chaperone-mediated autophagy in Huntington’s disease. J Neurosci. 2011;31:18492–505.

    PubMed  PubMed Central  Google Scholar 

  27. 27.

    Wu H, Chen S, Ammar AB, Xu J, Wu Q, Pan K, et al. Crosstalk between macroautophagy and chaperone-mediated autophagy: implications for the treatment of neurological diseases. Mol Neurobiol. 2015;52:1284–96.

    PubMed  Google Scholar 

  28. 28.

    Cai Z, Zeng W, Tao K, E Z, Wang B, Yang Q. Chaperone-mediated autophagy: roles in neuroprotection. Neurosci Bull. 2015;31:452–8.

    PubMed  PubMed Central  Google Scholar 

  29. 29.

    Koga H, Cuervo AM. Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration. Neurobiol Dis. 2011;43:29–37.

    PubMed  Google Scholar 

  30. 30.

    Park C, Cuervo AM. Selective autophagy: talking with the UPS. Cell Biochem Biophys. 2013;67:3–13.

    PubMed  PubMed Central  Google Scholar 

  31. 31.

    Benbrook DM, Long A. Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis. Exp Oncol. 2012;34:286–97.

    PubMed  Google Scholar 

  32. 32.

    Vilchez D, Saez I, Dillin A. The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat Commun. 2014;5:5659.

    PubMed  Google Scholar 

  33. 33.

    Wojcik S. Crosstalk between autophagy and proteasome protein degradation systems: possible implications for cancer therapy. Folia Histochem Cytobiol. 2013;51:249–64.

    PubMed  Google Scholar 

  34. 34.

    Nedelsky NB, Todd PK, Taylor JP. Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. Biochim Biophys Acta. 2008;1782:691–9.

    PubMed  PubMed Central  Google Scholar 

  35. 35.

    Strunk CJ, Platzbecker U, Thiede C, Schaich M, Illmer T, Kang Z, et al. Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics. Am J Hematol. 2009;84:308–9.

    PubMed  Google Scholar 

  36. 36.

    Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, et al. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget. 2012;3:490–501.

    PubMed  PubMed Central  Google Scholar 

  37. 37.

    Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, et al. BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. J Exp Med. 2016;213:1705–22.

    PubMed  PubMed Central  Google Scholar 

  38. 38.

    Saftig P, Tanaka Y, Lullmann-Rauch R, von Figura K. Disease model: LAMP-2 enlightens Danon disease. Trends Mol Med. 2001;7:37–39.

    PubMed  Google Scholar 

  39. 39.

    Rowland TJ, Sweet ME, Mestroni L, Taylor MR. Danon disease - dysregulation of autophagy in a multisystem disorder with cardiomyopathy. J Cell Sci. 2016;129:2135–43.

    PubMed  PubMed Central  Google Scholar 

  40. 40.

    Le Guyader-Peyrou S, Belot A, Maynadie M, Binder-Foucard F, Remontet L, Troussard X, et al. Cancer incidence in France over the 1980–2012 period: Hematological malignancies. Rev Epidemiol Sante Publique. 2016;64:103–12.

    PubMed  Google Scholar 

  41. 41.

    Cuervo AM, Dice JF. Age-related decline in chaperone-mediated autophagy. J Biol Chem. 2000;275:31505–13.

    PubMed  Google Scholar 

  42. 42.

    Huang J, Xu J, Pang S, Bai B, Yan B. Age-related decrease of the LAMP-2 gene expression in human leukocytes. Clin Biochem. 2012;45:1229–32.

    PubMed  Google Scholar 

Download references


This work was supported by INSERM, INCA (PRTK-045, 2013–2015), the Fondation ARC pour la Recherche contre le Cancer (Equipe labellisée 2014–2017 and 2018–2020) and the Association Laurette Fugain (ALF 2016/08). This work was also funded by the French government (National Research Agency, ANR) through the “investissement for the future” LABEX SIGNALIFE program reference #ANR-11-LABEX-0028-01. AD is the recipient of a fellowship from the Fondation pour la Recherche Médicale. SB is the recipient of a fellowship from the Fondation ARC. MZ is the recipient of a fellowship from the LABEX SIGNALIFE program. AP is supported by the ATIP-AVENIR research grant and by the St Louis Association for leukemia research. Finally, this work was also supported by the Conseil General des Alpes Maritimes and the Conseil Regional PACA & Corse. The authors greatly acknowledge the C3M Imaging Core Facility part of MICA (Microscopy and Imaging Platform Côte d’Azur).

Author information



Corresponding author

Correspondence to Guillaume Robert.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article has been retracted. Please see the retraction notice for more detail:"

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dubois, A., Furstoss, N., Calleja, A. et al. RETRACTED ARTICLE: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML. Leukemia 33, 1501–1513 (2019).

Download citation

Further reading